ADMA Biologics Reports Record Growth, Eyes $1.1B Future on Strategic Shifts

RAMSEY, N.J. and BOCA RATON, Fla. – February 25, 2026 – ADMA Biologics, Inc. today announced a landmark fiscal year, posting record-breaking 2025 financial results that underscore its successful transition to a profitable and rapidly growing biopharmaceutical player. The company reported total revenues of $510 million, a 20% increase from the previous year, largely propelled by the extraordinary performance of its flagship primary immunodeficiency treatment, ASCENIV, which saw its sales soar 51% to $363 million.

Buoyed by this momentum, the company confidently reiterated its ambitious long-term financial guidance, projecting it will surpass $1.1 billion in annual revenue and achieve more than $700 million in Adjusted EBITDA by fiscal year 2029. This forecast signals a new era of sustained growth and operational leverage for the end-to-end biologics manufacturer.

“2025 marked a year of disciplined execution, record performance and meaningful strategic progress for ADMA, and we are entering 2026 with significant momentum,” said Adam Grossman, President and Chief Executive Officer of ADMA, in a statement accompanying the results. He credited the performance to strong demand and adoption of ASCENIV, a vertically integrated manufacturing model, and enhanced plasma supply visibility.

Financial Strength and Ambitious Targets

ADMA's financial performance in 2025 showcased robust underlying health and profitability. The company’s Adjusted EBITDA grew by 40% year-over-year to $231 million, while its corporate gross margins expanded significantly, reaching 63.8% in the fourth quarter. This financial strength provides a solid foundation for the company's aggressive forward-looking targets, which imply a compound annual growth rate of approximately 20% for revenue and 30% for Adjusted EBITDA through 2029.

While ambitious, this guidance is supported by strong external market dynamics and positive analyst sentiment. The global immunoglobulin market, valued at over $14 billion in 2024, is projected to double by 2034, with the hyperimmune globulin segment that includes ASCENIV expected to grow at an even faster rate of nearly 9% annually. This industry-wide expansion, driven by an aging population and a rising prevalence of immune disorders, provides a powerful tailwind for ADMA's growth narrative. Financial analysts have largely endorsed this outlook, with consensus ratings leaning heavily toward "Strong Buy" and 12-month price targets suggesting significant potential upside.

The Engine of Growth: ASCENIV's Market Ascent

The driving force behind ADMA's success is ASCENIV, an intravenous immune globulin (IVIG) used to treat patients with primary immunodeficiency. The product’s staggering 51% revenue growth in 2025 reflects its increasing entrenchment with physicians and payers. The company attributes this to a growing body of real-world data validating the drug's efficacy, expanding payer coverage, and disciplined commercial execution. One peer-reviewed study highlighted in the company's update demonstrated that 71% of immunodeficient patients who had failed previous IVIG treatments showed clinical improvement after switching to ASCENIV.

Despite its success, ADMA believes ASCENIV is still in the early stages of its market penetration. The company is seeking to expand the drug's label to include pediatric patients as young as two, with a potential FDA approval anticipated in 2026 that could significantly broaden its addressable market. In a competitive IVIG landscape that includes global giants like Grifols and Takeda, ADMA is successfully carving out a valuable niche, protected by a patent portfolio that extends through at least 2035.

A Strategic Overhaul for a New Era

Beyond the impressive financial figures, ADMA's recent announcements reveal a company undergoing a strategic operational overhaul designed to secure future growth and efficiency. A key move is the appointment of Terry Kohler as the new Chief Financial Officer and Treasurer. Kohler brings a wealth of experience from his time as CFO at OptiNose, where he helped guide the company through an acquisition, and Verrica Pharmaceuticals. His expertise in capital allocation, working capital optimization, and disciplined financial strategy is seen as a critical asset as ADMA scales its operations and focuses on maximizing cash flow and shareholder value.

This leadership change is complemented by a shrewd realignment of the company's plasma network strategy. In December 2025, ADMA agreed to divest three of its plasma collection centers for $12 million in cash. Far from a retreat, this move is a pivot toward a more capital-efficient model. The company not only secured crucial long-term supply agreements with the purchaser but also expanded its access to a network of over 280 third-party plasma collection centers. This hybrid approach provides ADMA with a flexible, diversified, and durable plasma supply—a critical advantage in an industry often constrained by supply chain challenges—while freeing up capital and delivering expected cost savings beginning in 2026.

Beyond the Horizon: Building a Future Pipeline

While capitalizing on its current commercial success, ADMA is also investing in its long-term future with the advancement of its preclinical pipeline asset, SG-001. This investigative hyperimmune globulin is being developed to target S. pneumoniae, the bacterium responsible for pneumococcal disease. The product is designed to provide broad coverage against emerging and prevalent serotypes not fully addressed by existing vaccines.

ADMA plans to submit a pre-Investigational New Drug (IND) meeting package to the FDA in 2026, a step that could potentially allow the program to proceed directly into a pivotal registrational trial, suggesting an accelerated path to market. Management views SG-001 as a significant value driver, with a potential peak annual revenue opportunity estimated between $300 million and $500 million. This pipeline optionality demonstrates a forward-looking strategy that extends well beyond the company's current product portfolio, reinforcing its long-term potential in the specialty biologics space.